Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK3 | Q9NZJ5 | 4/20 | 0.63 |
| ▸ | RIPK2 | O43353 | 9/20 | 0.58 |
| ▸ | SRC | P12931 | 7/20 | 0.54 |
| ▸ | KIT | P10721 | 2/20 | 0.54 |
| ▸ | FLT3 | P36888 | 2/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.54 |
| ▸ | SIK1 | P57059 | 1/20 | 0.54 |
| ▸ | RIPK4 | P57078 | 1/20 | 0.54 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.54 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.54 |
| ▸ | DSTYK | Q6XUX3 | 1/20 | 0.54 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 5/20 | 0.52 |
| ▸ | EGFR | P00533 | 5/20 | 0.52 |
| ▸ | ABL2 | P42684 | 4/20 | 0.52 |
| ▸ | LCK | P06239 | 3/20 | 0.52 |
| ▸ | TEK | Q02763 | 2/20 | 0.52 |
| ▸ | PLK4 | O00444 | 1/20 | 0.52 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.52 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29503539 | 1.00 | EIF2AK3 (0.63) | EIF2AK3RIPK2SRCKITFLT3 | |
| SCHEMBL21084206 | 0.89 | EIF2AK3 (0.58) | EIF2AK3RIPK2SRCKITFLT3 | |
| SCHEMBL21084174 | 0.89 | EIF2AK3 (0.60) | EIF2AK3RIPK2SRCKITFLT3 | |
| SCHEMBL19743544 | 0.86 | EIF2AK3 (0.60) | EIF2AK3RIPK2SRCKITFLT3 | |
| SCHEMBL19743293 | 0.86 | SRC (0.59) | EIF2AK3RIPK2SRCKITFLT3 | |
| SCHEMBL29503455 | 0.86 | SRC (0.59) | EIF2AK3RIPK2SRCKITFLT3 | |
| SCHEMBL28273755 | 0.86 | FGR (0.63) | EIF2AK3RIPK2SRCKITFLT3 | |
| SCHEMBL21084200 | 0.82 | SRC (0.66) | EIF2AK3RIPK2SRCABL1EGFR | |
| SCHEMBL29503488 | 0.82 | SRC (0.66) | EIF2AK3RIPK2SRCABL1EGFR | |
| SCHEMBL8320799 | 0.81 | SRC (0.81) | RIPK2SRCKITFLT3ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833153-B2 | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-12-05 | — | — | US | disclosed |
| EP-3472165-B1 | N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2023-09-06 | — | — | EP | disclosed |
| US-20230107393-A1 | N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-04-06 | — | — | US | disclosed |
| US-11491158-B2 | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2022-11-08 | — | — | US | disclosed |
| CN-109311894-B | N- (substituted-phenyl) -sulfonamide derivatives as kinase inhibitors | 内尔维阿诺医学科学有限公司 | 2022-03-22 | — | — | CN | disclosed |
| US-20210128563-A1 | N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2021-05-06 | — | — | US | disclosed |
| US-10918642-B2 | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2021-02-16 | — | — | US | disclosed |
| US-20200121686-A1 | N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2020-04-23 | — | — | US | disclosed |
| US-10561660-B2 | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2020-02-18 | — | — | US | disclosed |
| US-20190201406-A1 | N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-07-04 | — | — | US | disclosed |
| EP-3472165-A1 | N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2019-04-24 | — | — | EP | disclosed |
| WO-2017220477-A1 | N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230107393-A1 | N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS | ATF4, MAP3K1, MAP3K6 | EIF2AK3 58/4885RIPK2 310/4885SRC 161/4885 |
| US-20190201406-A1 | N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS | ATF4, MAP3K1, MAP3K6 | EIF2AK3 58/4885RIPK2 310/4885SRC 161/4885 |
| US-11491158-B2 | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors | ATF4, MAP3K1, MAP3K6 | EIF2AK3 58/4885RIPK2 310/4885SRC 161/4885 |
| US-11833153-B2 | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors | ATF4, MAP3K1, MAP3K6 | EIF2AK3 58/4885RIPK2 310/4885SRC 161/4885 |
| US-20210128563-A1 | N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS | ATF4, MAP3K1, MAP3K6 | EIF2AK3 58/4885RIPK2 310/4885SRC 161/4885 |
| US-10918642-B2 | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors | ATF4, MAP3K1, MAP3K6 | EIF2AK3 58/4885RIPK2 310/4885SRC 161/4885 |
| US-20200121686-A1 | N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS | ATF4, MAP3K1, MAP3K6 | EIF2AK3 58/4885RIPK2 310/4885SRC 161/4885 |
| US-10561660-B2 | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors | ATF4, MAP3K1, MAP3K6 | EIF2AK3 58/4885RIPK2 310/4885SRC 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.